Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study. [PDF]
Front Med (Lausanne)Doménech-Serrano J +5 more
europepmc +1 more source
Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients. [PDF]
Int J Equity HealthOfanoa S +5 more
europepmc +1 more source
Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout. [PDF]
Int J Med Sci, 2021 Yen FS +5 more
europepmc +1 more source
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial. [PDF]
ACR Open RheumatolYu Y +14 more
europepmc +1 more source
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database. [PDF]
Rheumatol TherPadnick-Silver L +5 more
europepmc +1 more source
A single-centre experience of febuxostat as a second-line urate-lowering therapy. [PDF]
Malays Fam Physician, 2021 Ong SG, Ding HJ.
europepmc +1 more source
Chronic tophaceous gout presenting as acute arthritis during an acute illness: a case report [PDF]
, 2008 Abhijeet Dhoble +2 more
core +1 more source
Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. [PDF]
Ther Adv Musculoskelet Dis, 2021 Sharma G, Dubey A, Nolkha N, Singh JA.
europepmc +1 more source
Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout [PDF]
core +1 more source